PECAVAPTAN |
PECAVAPTAN : Antagonist of AVPR1A and AVPR2
Probe Summary
Selectivity
Potency
In Vivo
Control Compounds
Chemical Information
References
Vendors
Download
Probe Summary
| Targets | Biochemical/Biophysical Potency | Cellular Potency |
|---|---|---|
| AVPR1A |
|
|
| AVPR2 |
|
|
Antagonist
100 nM
Selectivity
In Vitro Selectivity Assessment
Potency Assay Off-Target:
Selectivity within target family: Binding assay: ADRA1B (Ki > 10 µM), OXTR (Oxytocin receptor, Ki = ...
Potency Cellular
In Vitro
AVPR1A
Mode of Action: Antagonist
Structure-Activity-Relationship data available? No
DOI Reference: 10.1097/FJC.0000000000000677
AVPR2
Mode of Action: Antagonist
Structure-Activity-Relationship data available? No
DOI Reference: 10.1097/FJC.0000000000000677
In Vivo Validations
Rat
Dose: 1.0 mg/Kg
Route of delivery:
Oral
Plasma half life:
8.5 h
Tmax:
2.0 h
Area Under the Curve::
1.2 Kg*h/L
Bioavailability:
118%
DOI Reference: 10.1097/FJC.0000000000000677
Dog
Dose: 0.5 mg/Kg
Route of delivery:
Oral
Plasma half life:
7.0 h
Tmax:
1.0 h
Area Under the Curve::
1.6 Kg*h/L
Bioavailability:
58%
DOI Reference: 10.1097/FJC.0000000000000677
Negative Control Compounds
BAY-2297
Notes: BAY-2297: Binding assay: AVPR1A (Ki > 10 µM), AVPR2 (Ki > 10 µM); Cell-based assay: AVPR1A (IC50 > 10 µM); AVPR2 (IC50 > 10 µM); AVPR1B (Ki > 10 µM), OXTR (Ki > 10 µM) Eurofins Panlabs safety screen of 80 targets at 10 µM: clean; Eurofins kinase panel (378 kinases) at 10 µM: clean
SMILES:
C(c1cncn1c1cccc(c1)[Cl])N1C(N(C[C@@H](C(F)(F)F)O)C(c2ccc(cc2)[Cl])=N1)=O
Chemical Information
| Molecular Formula | C22H19Cl2F3N6O3 |
| SMILEs | C[C@H](O)c1nc(Cn2nc(-c3ccc(Cl)cc3)n(C[C@H](O)C(F)(F)F)c2=O)nn1-c1cccc(Cl)c1 |
| InChI | InChI=1S/C22H19Cl2F3N6O3/c1-12(34)19-28-18(29-33(19)16-4-2-3-15(24)9-16)11-32-21(36)31(10-17(35)22(25,26)27)20(30-32)13-5-7-14(23)8-6-13/h2-9,12,17,34-35H,10-11H2,1H3/t12-,17-/m0/s1 |
| Molecular weight | 542.08 Da |
| AlogP | 3.624100000000002 |
| HBond acceptors | 9 |
| HBond donors | 2 |
| Atoms | 55 |